Document is current
Any future updates will be listed below
-
Authors
Schmauch, Benoît https://orcid.org/0000-0002-9478-6395
Herpin, Loïc https://orcid.org/0000-0002-5535-0601
Olivier, Antoine
Duboudin, Thomas
Dubois, Rémy
Gillet, Lucie
Filiot, Alexandre
Schiratti, Jean-Baptiste
Di Proietto, Valentina
Le Corre, Delphine
Bourgoin, Alexandre
Taïeb, Julien
Emile, Jean-François https://orcid.org/0000-0002-6073-4466
Fridman, Wolf H. https://orcid.org/0000-0002-1332-0973
Pronier, Elodie
Laurent-Puig, Pierre https://orcid.org/0000-0001-8475-5459
Durand, Eric Y.
- License Information
-
More Information
Article History
Received: 21 August 2024
Accepted: 12 November 2025
First Online: 27 November 2025
Competing interests
: Persons affiliated with Owkin own stocks in the company (BS, LH, AO, TD, RD, LG, JBS, VDP, EP, ED). JT has received honoraria as a speaker or in an advisory role from Sanofi, Roche, Merck Serono, Amgen, Servier, Pierre Fabre, Lilly, AstraZeneca and MSD. WHF is a consultant for Novartis, Adaptimmune, Anaveon, Catalym, OSE Immunotherapeutic, Oxford Biotherapeutics, Genenta and Parthenon. PLP has received honoraria as a speaker or in an advisory role from ESMO, Amgen, Servier, Pierre Fabre, Biocartis, and stocks from Methys DX. The remaining authors declare no competing interests.
